Norway Life Science 2026: Building the Future
The Norway Life Science Conference 2026 will address the areas where Norway has world-leading research. How can we, based on these areas, facilitate knowledge-based innovation, a competitive life sciences industry, and increased national value creation?
Date:
Place:
Meet Ullevål, Ullevål Stadion, Oslo
On 10 and 11 February, 2026, Norway Life Science 2026 will take place, Norway's leading conference for health and life sciences.
Here, industry, academia, and public actors meet to collaboratively develop Norwegian life sciences.
We will address the framework conditions for innovation and growth, how to increase access to capital, and make it attractive for more companies to establish themselves in Norway.
Within life sciences, Norwegian research environments are world-leading in radiopharmacy, neuroscience, ocean health, health data, global health, one health, and precision medicine. These topics form the framework for the conference.
Highlights from the programme
At the conference, you will hear from the leading research environments, key leaders in Norway's healthcare sector, globally leading pharmaceutical companies, startups, investors, and decision-makers.
- Minister of Research and Higher Education Sigrun Aasland will open the conference.
- Christian Rommel, Global Head of Research and Development at Bayer, will deliver a keynote on developing the life sciences industry in Norway from a global perspective.
- Minister of Health Jan Christian Vestre will participate in a panel discussion on health preparedness and vaccination alongside Rino Rappuoli, head of the European Vaccine Hub, and Tore Godal (former WHO).
Registration opens and the programme will be published in early December.
Collaboration between researchers, industry, public actors, and investors
The conference is hosted as an Oslo Science City Arena event in collaboration with leading knowledge and industry partners. The University of Oslo is the organizer together with Oslo Science City, Oslo University Hospital, NMBU - Norwegian University of Life Sciences, SINTEF, Legemiddelindustrien (LMI), Oslo Cancer Cluster, The Life Science Cluster and Norway Health Tech. Industry partners are AstraZeneca, GSK, Novartis, Novo Nordisk, Roche, Thermo Fisher, AbbVie and Bayer.